Microdosing Mounjaro, cold sensitivity, and switching to Wegovy: your questions answered

Can you microdose Mounjaro?#

No. Microdosing Mounjaro is not recommended, and in most cases it simply is not possible to do safely. The Mounjaro KwikPen is an auto-injector designed to deliver fixed doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. There is no mechanism within the pen to dial down to 0.5mg or 1mg. Anyone attempting this would need to manipulate or partially depress the device, which risks inaccurate dosing, contamination, and damage to the medication.

UK clinical guidelines, including NICE Technology Appraisal TA1026 and the approved Summary of Product Characteristics, specify a starting dose of 2.5mg weekly for four weeks before any titration. That starting dose already exists precisely to minimise side effects during the adjustment period. There is no evidence base that going below 2.5mg produces a better outcome, and doing so is off-label without any clinical oversight.

Why do people try to microdose in the first place?#

It is worth being honest about the reasons people look into this, because they are usually legitimate concerns being addressed in the wrong way.

Side effects. Nausea, fatigue, and digestive discomfort are common in the first few weeks on Mounjaro, particularly after dose increases. It is understandable to want to take the edge off. But the 2.5mg starting dose is already the manufacturer's answer to that problem. If side effects at 2.5mg are severe, the right conversation to have is with your prescriber about whether to delay the titration schedule or take supportive measures, not whether to split the dose.

Cost. Mounjaro is not cheap on a private prescription. At Totiva, for example, the 2.5mg pen is £136.88 per month and the 15mg pen is £268.88. It is tempting to think that stretching a pen across more time or halving doses could reduce the monthly outlay. In practice, underdosing is likely to reduce effectiveness without meaningfully reducing cost, since you still need a prescription and the pen itself.

Anxiety about "jumping" doses. Some people feel nervous about moving from 2.5mg to 5mg and wonder if there is a softer middle ground. Again, the right answer is a conversation with your prescriber about slowing your titration, not attempting DIY dosing.

The risks of pen manipulation#

Mounjaro KwikPens are single-use, auto-locking devices. The manufacturer explicitly advises against tampering. Attempting to partially depress the plunger or reuse a pen carries several real risks:

• Inaccurate dosing. You cannot reliably measure a sub-2.5mg dose from a fixed-dose pen. You may end up with anything from a trace amount to a full dose without knowing.
• Contamination. Re-exposing the needle or re-entering the pen increases the risk of bacterial contamination at the injection site.
• Medication degradation. Once a pen has been activated, the integrity of the remaining medication cannot be guaranteed, especially if it has been removed from refrigeration.
• Prescription implications. Manipulating prescription devices may breach the terms of your prescription and could result in your provider withdrawing treatment.

Some patients ask about compounded tirzepatide as an alternative route to lower doses. It is important to be clear on this: compounded tirzepatide is not licensed in the UK. The MHRA has not approved any compounded version of tirzepatide for sale, and purchasing it from unlicensed sources carries significant safety risks, including unknown concentration, purity, and sterility. If a website is selling compounded tirzepatide in the UK, it is operating outside the law.

What to do instead#

If you are struggling with side effects or costs, there are better options than microdosing:

• Talk to your prescriber about pausing your titration. Many clinicians are happy to keep patients at 2.5mg or 5mg for longer than four weeks if tolerability is an issue. Clinical trials showed meaningful weight loss even at lower doses.
• Review your injection timing. Some people find injecting in the evening reduces daytime nausea.
• Look at your eating habits. Eating smaller, lower-fat meals reduces GI side effects significantly.
• Ask about dose reduction. If you are on a higher dose and struggling, stepping back down to a previously tolerated dose is a legitimate clinical decision, not a failure.
• Consider whether Mounjaro is the right medication for you. Some people tolerate Wegovy (semaglutide) better, and others prefer oral options. There is no single "best" GLP-1 medication for everyone.

If you are already on Mounjaro through Totiva and want to discuss your dose or side effects, your clinical team is there for exactly that conversation. Adjusting your approach with proper oversight is always safer than experimenting alone.

Why does Mounjaro make some people feel cold?#

Feeling unusually cold while taking Mounjaro is not listed as an official side effect in the Summary of Product Characteristics, but it is a common enough observation among patients that it is worth explaining properly.

The short answer is: Mounjaro itself probably is not causing this directly. The cold sensitivity most people experience is a downstream effect of what Mounjaro does rather than a direct pharmacological action.

The fat loss connection#

Subcutaneous fat (the layer just beneath your skin) acts as a natural insulator. It traps heat and buffers you against ambient temperature. When you lose weight quickly, as many people do on tirzepatide, you lose some of that insulation. The result is that you feel the cold more than you did before, particularly in your extremities.

This is the same reason that people who are naturally lean often report feeling cold more easily than those carrying more body fat. It is physiology, not pathology.

Reduced calorie intake and metabolism#

Mounjaro works partly by reducing appetite significantly. When you eat less, your body produces less heat through digestion (a process called diet-induced thermogenesis). This subtle metabolic shift can lower your baseline body temperature slightly, particularly in the first few months of treatment when caloric restriction is most pronounced.

Worth ruling out: nutritional factors#

If the cold sensitivity is persistent or severe, it is worth asking your GP to check a few things:

• Iron deficiency anaemia. Feeling cold is a classic symptom of low iron, and iron intake can drop on a significantly reduced-calorie diet.
• Thyroid function. An underactive thyroid causes cold intolerance and can either pre-exist or, rarely, be unmasked during significant metabolic change.
• Vitamin B12. Deficiency can affect circulation and contribute to cold hands and feet. People eating significantly less may not be getting adequate B12 from food.

None of these are common consequences of Mounjaro, but they are worth excluding if you are genuinely struggling with temperature regulation rather than just noticing you feel a bit chillier than before.

Practical ways to manage it#

• Layer up, particularly in autumn and winter. This sounds obvious, but your insulation needs have genuinely changed.
• Keep moving. Physical activity generates heat and supports circulation. The UK Chief Medical Officers recommend at least 150 minutes of moderate activity per week, which is good advice for multiple reasons on a GLP-1 programme.
• Eat enough protein. Protein has the highest thermic effect of any macronutrient and supports muscle retention, both of which help maintain a healthier metabolic rate during weight loss.
• Ensure your diet includes iron-rich foods (lean red meat, lentils, fortified cereals) and B12 sources (meat, fish, dairy, or supplements if needed).

When to seek medical advice#

Contact your GP or prescriber if:

• The cold sensitivity is severe or came on suddenly
• You have other symptoms alongside it (fatigue, hair thinning, constipation, dry skin) that could point to thyroid issues
• You are also experiencing shakiness or sweating alongside feeling cold (especially if you take insulin or sulfonylureas, as this could indicate hypoglycaemia)
• The sensation does not improve over several weeks

Switching from Mounjaro to Wegovy#

Switching between GLP-1 medications is something more people are asking about, and for a few different reasons. Some have found Mounjaro's side effects difficult to manage. Others are weighing up the cost difference, particularly following price increases in 2025. And some simply want to try a different approach after a plateau.

The reassuring news is that switching from Mounjaro (tirzepatide) to Wegovy (semaglutide) is clinically straightforward when done properly.

Understanding the difference between the two#

Both medications reduce appetite and body weight, but they work through slightly different mechanisms. Wegovy acts on GLP-1 receptors only. Mounjaro acts on both GLP-1 and GIP receptors, which is one reason tirzepatide tends to produce greater average weight loss in clinical trials (up to 20.9% at 15mg in SURMOUNT-1, compared to approximately 15% with semaglutide 2.4mg in STEP-1).

Switching from Mounjaro to Wegovy may mean accepting somewhat less average weight loss potential, though individual responses vary considerably. For some people, the trade-off is worth it for better tolerability, lower cost, or personal preference.

The dosing gap#

Because these are different medications, they are not interchangeable on the same day. Most UK clinical protocols recommend waiting 28 days between your last Mounjaro dose and starting Wegovy, though some providers use a shorter 7-day gap depending on individual circumstances.

The gap exists to allow tirzepatide to clear from your system and to reduce the risk of overlapping GLP-1 activity, which could increase side effects. During this window, some weight regain is possible, as your appetite suppression reduces. This is typically temporary and resolves once semaglutide reaches therapeutic levels, but it is worth being prepared for psychologically.

Dosing when you switch#

You generally do not need to restart from the lowest Wegovy dose (0.25mg) if you have been on Mounjaro for some time. Your prescriber will review your treatment history and recommend an appropriate starting point for Wegovy. This might be 0.5mg or higher, depending on what dose of Mounjaro you were on and how long you have been using it.

Do not attempt to start Wegovy at the highest dose unsupervised. Even with tolerance built on Mounjaro, the mechanisms are not identical and your body needs time to adjust to semaglutide specifically.

Cost comparison#

At Totiva, Wegovy injections start from £92.88 per month for the lower doses (0.25mg, 0.5mg, 1mg), rising to £188.88 for the 2.4mg maintenance dose. Mounjaro ranges from £136.88 at 2.5mg to £268.88 at 15mg. For patients on higher Mounjaro doses, Wegovy at its maintenance dose may represent a meaningful monthly saving, though this depends on which doses you are actually comparing.

There is also a Wegovy tablet option (semaglutide oral) available at Totiva for those who prefer to avoid injections, starting from £99.00 per month.

Why people switch: common reasons#

• Persistent nausea or GI side effects on Mounjaro that did not settle after several months
• Cost. Monthly Mounjaro costs at higher doses are significant. For some patients, Wegovy at a maintenance dose is more sustainable long-term.
• Preference for an oral medication. The tablet form of semaglutide is an option that Mounjaro does not currently have.
• Weight loss plateau. Occasionally, switching mechanisms can restart progress, though this is not guaranteed.

How to make the switch#

The process is straightforward:

1. Speak to your prescriber. Do not just stop Mounjaro and start Wegovy from a different source without clinical oversight.
2. Agree a gap period (usually 7 to 28 days depending on your clinical situation).
3. Get a Wegovy prescription at an appropriate starting dose based on your treatment history.
4. Monitor how you respond in the first four weeks and keep in touch with your prescribing team.

If you are thinking about making this switch, Totiva's weight loss consultation is a good starting point. The online consultation is free, you only pay after approval, and no subscription is required. For weight loss medications specifically, a short video call with a clinician is required before your first prescription, which is a regulatory requirement but also genuinely useful when you are navigating a medication change.

A note on getting support#

Whether you are reconsidering your dose, managing an unexpected side effect, or weighing up whether Mounjaro or Wegovy is the better long-term fit, the most important thing is not to make those decisions alone. These are prescription medications with real physiological effects, and the right dose for you depends on your individual health, your response to treatment, and your goals.

If you want pharmacist-led guidance without being locked into a subscription programme, you can start a free weight loss consultation at Totiva. A clinician will review your situation and recommend an approach based on your actual circumstances, not a one-size-fits-all protocol.